Added to YB: 2024-08-26
Pitch date: 2024-08-26
GOSS [bullish]
Gossamer Bio, Inc.
+125.36%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States.
Market Cap
$523.1M
Pitch Price
$0.94
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.62
P/E
-3.29
EV/Sales
12.39
Sector
Biotechnology
Category
N/A
Show full summary:
GOSSAMER BIO INC GOSS
A summary for this pitch has not been created yet.
Read full article (0 min)